Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$52.2M | -$34.4M | -$90.9M | -$102M | -$167M | -$315M |
| Net income | -$53.4M | -$32.6M | -$89.1M | -$96.0M | -$152M | -$300M |
| EPS (diluted) | -$166.93 | -$2.43 | -$3.35 | -$2.25 | -$2.75 | -$4.66 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$34.8M | -$23.7M | -$67.6M | -$92.2M | -$135M | -$241M |
| Capital expenditures | $99.0K | $0.00 | $62.0K | $63.0K | $972K | $630K |
| Free cash flow | -$34.9M | -$23.7M | -$67.7M | -$92.2M | -$136M | -$242M |
| Share buybacks | — | — | — | $0.00 | $13.0K | $0.00 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $53.7M | $79.7M | $43.5M | $45.7M | $92.6M | $355M |
| Total assets | $54.6M | $83.7M | $131M | $176M | $656M | $735M |
| Total liabilities | $4.33M | $14.2M | $54.5M | $73.9M | $78.5M | $130M |
| Long-term debt | $0.00 | $4.92M | $24.8M | $49.9M | $50.7M | $74.8M |
| Shareholders' equity | -$89.3M | $69.6M | $76.9M | $102M | $577M | $605M |
| Retained earnings | -$91.4M | -$124M | -$213M | -$309M | -$461M | -$761M |
| Shares (wtd avg diluted) | — | 13.4M | 26.6M | 42.7M | 55.3M | 64.2M |
Every figure is extracted from Vera Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.